Abstract
Background: Although obesity is a recognized risk factor contributing to the onset and progression of overactive bladder (OAB), the existing evidence linking lipid accumulation products (LAPs) and the visceral adiposity index (VAI) to OAB remains scarce and subject to debate. Hence, this study was conducted to evaluate the associations between VAI, LAP, and the occurrence of OAB. Methods: The information utilized in this research was sourced from the National Health and Nutrition Examination Survey (NHANES), spanning the years 2005 to 2018. The majority of the data pertaining to OAB relied on self-administered questionnaires. To assess the relationships between VAI, LAP, and OAB, we employed multivariate logistic regression models, trend analysis, and subgroup evaluations. Results: The study encompassed a total of 70,190 participants, with 22,928 individuals diagnosed with OAB and 5,776 serving as controls. After accounting for potential confounding factors, a statistically significant positive relationship was noted between both the visceral adiposity index (VAI) and the lipid accumulation product (LAP), as well as the occurrence of overactive bladder (OAB). Respectively, individuals in the highest quartiles of LAP and VAI demonstrated a 56% (OR = 1.555, 95% CI: 1.376 to 1.758) and 22% (OR = 1.225, 95% CI: 1.084 to 1.384) increased probability of OAB when compared to those in the lowest quartile. Additional subgroup analyses revealed that the observed associations were particularly evident in participants under the age of 60 and among women. Conclusion: This study's findings suggest that an increase in both the visceral adiposity index (VAI) and lipid accumulation product (LAP) is associated with a greater occurrence of overactive bladder (OAB), hinting at their possible use as predictive indicators for OAB.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval and consent were not required as this study was based on publicly available deidentified data(https://www.cdc.gov/nchs/nhanes/index.htm)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All files are available from the NHANES database (https://www.cdc.gov/nchs/nhanes/index.htm)
